Patents Examined by Jagadishwar R. Samala
  • Patent number: 10660974
    Abstract: Dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and ?* acceptor group-containing dioxetane based chemiluminescence probes can be included in compositions. The chemiluminescence probes are useful for both diagnostics and in vivo imaging.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: May 26, 2020
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Doron Shabat, Ronit Satchi-Fainaro, Nir Hananya, Ori Green, Tal Eilon
  • Patent number: 10653806
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: May 19, 2020
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Hassan Shallal
  • Patent number: 10646592
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: May 12, 2020
    Assignee: Translatum Medicus Inc.
    Inventor: Shelley Romayne Boyd
  • Patent number: 10636536
    Abstract: The present disclosure relates to systems and methods for producing tailored solutions or medicaments containing radioactive isotopes (e.g., alpha particle emitting radioactive isotopes). The solutions may be produced by appropriate aging and separation steps. Therapeutically effective amounts of Pb-212 and/or Bi-213 may thus be obtained.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: April 28, 2020
    Assignee: RADTRAN LLC
    Inventor: Saleem S. Drera
  • Patent number: 10620215
    Abstract: The present invention relates to a fluorescence sensor capable of real-time imaging for measuring a cellular thiol level. The present invention reveals that the fluorescence intensity of the fluorescent real-time SH group-tracer (FreSH-Tracer) of the present invention increases or decreases continuously, ratiometrically or reversibly depending on the thiol level in living cells, and thus can be usefully used as a biosensor which is remarkably susceptible to quantitative or qualitative real-time detection of the cellular thiol level in living cells.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: April 14, 2020
    Assignees: Cell2In, Inc., Korea University Reserach and Business Foundation, SNU R&DB Foundation
    Inventors: In-Gyu Kim, Ki Hang Choi, Eui Man Jeong, Heun Soo Kang
  • Patent number: 10597409
    Abstract: The invention relates to complexing agents of formula (I) in which A1, A2, A3 and R1 are as defined in the description. The invention also relates to lanthanide complexes obtained from said complexing agents. The invention can be used for marking biological molecules.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 24, 2020
    Assignees: CISBIO BIOASSAYS, UNIVERSITE PAUL SABATIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Laurent Lamarque, Claude Picard, Chantal Galaup, Nadine Leygue, Jurriaan Zwier, Emmanuel Bourrier
  • Patent number: 10597340
    Abstract: Provided herein are methods and compositions for the electrochemical selective radiofluorination of aromatic molecules. The resulting fluorine-18 labeled compounds are ideal radionuclides for use in Positron Emission Tomography (PET); they are also difficult to radiolabel efficiently and with high specific activity using existing approaches. For example, radiopharmaceuticals such as [F18]L-DOPA, which is indispensable in PET brain disease imaging, may be made electrochemically with high radiochemical yield and high specific activity using 18F-. The invention process described herein opens new possibilities and provides wider access to PET tracers such as 18F-L-Dopa, since 18F- is much more widely available than the 18F2, currently used for synthesis of electron rich substrates.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: March 24, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Saman Sadeghi, Qinggang He, Artem Lebedev
  • Patent number: 10596277
    Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.
    Type: Grant
    Filed: November 17, 2018
    Date of Patent: March 24, 2020
    Assignee: IGL Pharma, Inc.
    Inventors: Jaime Simon, R. Keith Frank, David A. Wilson
  • Patent number: 10561749
    Abstract: Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where R1, R2, and Y are as defined.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 18, 2020
    Assignees: Kyoto University, ARKRAY, Inc.
    Inventors: Hideo Saji, Hiroyuki Kimura, Anna Miyazaki, Hirokazu Matsuda, Shuichi Nakanishi
  • Patent number: 10561745
    Abstract: Materials and methods for synthesizing magnetic core/gold shell nanoparticles and magneto-plasmonic nanostars are provided. Formulations comprising nanoparticles optionally bound to or co-loaded with a therapeutic agent encapsulated within liposomes are provided. A method for treating diseases (e.g., brain diseases) in a subject by administering to the subject a formulation comprising the nanoparticle formulation is also provided. Further, a method is provided for imaging a target site of a subject following the administering of the nanoparticle formulations.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: February 18, 2020
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Asahi Tomitaka, Madhavan Nair
  • Patent number: 10562835
    Abstract: Disclosed herein are embodiments of a method for producing thorium-226. The method comprises separating thorium-226 from uranium-230 to produce a solution of thorium-226 in a solvent, such as a chelating buffer, suitable for direct labeling by a chelate. The thorium-226 may be separated from the uranium-230 using extraction chromatography. The extraction may be repeated multiple times as additional thorium-226 is produced by uranium-230 decay.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 18, 2020
    Assignee: Triad National Security, LLC
    Inventors: Michael E. Fassbender, Tara E. Mastren
  • Patent number: 10556916
    Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula. The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Noriko Sato, Haitao Wu, Gary L. Griffiths, Peter L. Choyke
  • Patent number: 10544167
    Abstract: The present disclosure relates to the field of synthetic pharmaceutical chemistry and biology. The disclosure provides a compound of Formula I and a process of preparation thereof. The disclosure further relates to methods and use of Formula I compounds as stimuli-responsive probes. Said Formula I compounds are employed for detecting and quantifying reactive oxygen species (ROS), and have related applications including but not limited fluorescence spectroscopy, diagnostics, treatment, imaging and biomedical applications.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 28, 2020
    Assignee: Jawaharlal Nehru Centre for Advanced Scientific Research
    Inventors: Govindaraju Thimmaiah, Nagarjun Narayanaswamy
  • Patent number: 10543481
    Abstract: Methods of preparing fluorinated compounds by carboxylative fluorination using fluoride are contained herein. Fluorinated compounds are provided. Methods of using fluorinated compounds are contained herein.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: January 28, 2020
    Assignee: TRUSTEES OF PRINCETON UNIVESITY
    Inventors: John T. Groves, Xiongyi Huang
  • Patent number: 10537650
    Abstract: The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: January 21, 2020
    Assignee: University of Massachusetts
    Inventors: Brian D. Gray, Mary Rusckowski, Koon Y. Pak
  • Patent number: 10537647
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: January 21, 2020
    Assignee: Translatum Medicus Inc.
    Inventor: Shelley Romayne Boyd
  • Patent number: 10525149
    Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: January 7, 2020
    Assignee: MediBeacon Inc.
    Inventors: Richard B. Dorshow, Thomas E. Rogers
  • Patent number: 10526317
    Abstract: Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 7, 2020
    Assignees: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann, Marie Christine Nlend
  • Patent number: 10519160
    Abstract: Provided herein are radiolabeled compounds useful for non-invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography. The present application also provides unlabeled compounds useful in methods of treating diseases of the central nervous system or disease of the peripheral nervous system. Methods for preparing radiolabeled compounds, preparing unlabeled compounds, and diagnostic methods using labeled or unlabeled compounds are also provided.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: December 31, 2019
    Assignee: The General Hospital Corporation
    Inventors: Genevieve Van de Bittner, Jacob M. Hooker
  • Patent number: 10500293
    Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: December 10, 2019
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson